
- /
- Supported exchanges
- / F
- / GS71.F
GSK plc (GS71 F) stock market data APIs
GSK plc Financial Data Overview
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, United Kingdom.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get GSK plc data using free add-ons & libraries
Get GSK plc Fundamental Data
GSK plc Fundamental data includes:
- Net Revenue: 31 631 M
- EBITDA: 9 291 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-30
- EPS/Forecast: 0.43
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GSK plc News

GSK Commits $30B to Boost U.S. Pharma Expansion
This article first appeared on GuruFocus. GSK (GSK, Financials) said Wednesday it will invest at least $30 billion in U.S. operations over the next five years, expanding research, development and man...


GSK Just Dropped $30 Billion on America's Biotech Future--Here's What That Buys
This article first appeared on GuruFocus. GSK (NYSE:GSK) is leaning hard into its U.S. footprint with a $30 billion commitment over the next five yearsan investment wave that spans drug discovery, cl...

GSK to Invest $30B in U.S. R&D and Manufacturing Over 5 Years
GSK plc GSK has unveiled a $30 billion investment plan in research and development (R&D) and supply chain infrastructure in the United States, which will be executed over the next five years. GSK’s...

LLY's $5B Virginia Plant Plan: Will U.S. Manufacturing Shift Pay Off?
Eli Lilly and Company LLY announced plans to spend $5 billion to build a massive new manufacturing facility in Virginia as the Trump administration pushes companies to boost production in the United S...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.